LFTD Partners Inc.

LIFD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-24.9M $-1.9M $2.2M $7.2M $5.8M $-1.5M $-1.2M $-220.6K
Depreciation & Amortization $552.9K $520.6K $425.6K $191.5K $90.1K $16.4K $0 —
Depreciation — — — — $65.7K $15.0K $0 —
Amortization — — — — — — — —
Stock-Based Compensation — — — $0 $0 $1.4M $874.2K $72.5K
Net Cash from Operating Activities $1.3M $-960.1K $638.9K $3.0M $5.6M $-338.0K $-611.5K $-32.2K
Investing Activities
Capital Expenditures $121.6K $313.8K $789.7K $916.1K $368.2K $70.1K $0 —
Business Acquisitions $0 $200.0K $342.1K $0 $0 $3.1M $0 —
Net Cash from Investing Activities $-121.6K $-479.6K $-2.5M $-916.1K $-446.7K $-3.5M $-2.1M $0
Financing Activities
Dividends Paid — — — — $11.8K $15.0K $0 —
Stock Repurchases $0 $240.2K $0 $150.0K $34.2K $34.2K — —
Net Cash from Financing Activities $-2.6M $-771.0K $3.7M $-193.4K $-4.0M $-98.0K $7.1M $32.2K
Net Change in Cash — — — — $1.2M $-3.9M $4.4M $0
Free Cash Flow $1.2M $-1.3M $-150.7K $2.1M $5.3M $-408.2K $-611.5K —
← Newer Page 1 of 2 Older →